Literature DB >> 23103539

Glycine ameliorates liver injury and vitamin D deficiency induced by bile duct ligation.

Chiung-Yu Chen1, Bei-Tzu Wang, Zih-Ciang Wu, Wen-Ting Yu, Po-Ju Lin, Wei-Lun Tsai, Shu-Chu Shiesh.   

Abstract

BACKGROUND: Patients with chronic liver disease had lower serum concentrations 25-hydroxyvitamin D (25OHD). Glycine, a nonessential amino acid, exerts anti-inflammatory, cytoprotective, and immunomodulatory properties. This study aimed to establish a tandem mass spectrometry assay to measure 25OHD in guinea pigs serum and to investigate the effects of glycine against the liver damage induced by bile duct ligation (BDL).
METHODS: BDL was performed on male guinea pigs. Glycine, alanine, serine or tyrosine was given by intraperitoneal injection. The animals were sacrificed and examined at 7 and 14 days after BDL. Serum concentrations of total bilirubin and aminotransferase were measured. Serum concentrations of 25OHD2 and 25OHD3 were measured by API 5000 mass spectrometer. In addition, oxidative stress was assessed by serum ischemia-modified albumin (IMA) and hepatic malondialdehyde (MDA), and apoptosis by hepatic caspase 3 activities.
RESULTS: Serum 25OHD concentrations were decreased around 50% in the BDL group at days 7 and 14 post ligation, compared to sham (mean 65.3 ng/ml, p<0.005). Glycine but not other amino acid treatment blunted the reduced serum 25OHD (52.6 ng/ml, p<0.05) resulting from BDL. The concentrations of 25OHD were negatively associated with concentrations of IMA (r=-0.305, p<0.05) and caspase 3 (r=-0.562, p<0.0001). At day-14 post ligation, glycine treatment also ameliorated liver damage indicated by serum AST (p<0.005), ALT (p<0.05) and hepatic caspase 3 activities (p<0.05) and oxidative stress.
CONCLUSION: Our results indicate that glycine may protect against BDL-induced liver injury through attenuation of oxidative stress, apoptosis and the vitamin D deficiency.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103539     DOI: 10.1016/j.cca.2012.10.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative.

Authors:  Wenyu Chen; Ming Yao; Miaomiao Chen; Zhao Ou; Qi Yang; Yanbin He; Ning Zhang; Min Deng; Yuqi Wu; Rongchang Chen; Xiaoli Tan; Ziqing Kong
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 2.  Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D.

Authors:  Shahida Khan; Ashraf Ali; Sarah Khan; Ahmed Bakillah; Ghazi Damanhouri; Aziz Khan; Ahmad Makki; Ibtehal AlAnsari; Naheed Banu
Journal:  Nutr Metab (Lond)       Date:  2018-02-09       Impact factor: 4.169

3.  Chondroitin Sulfate Protects the Liver in an Experimental Model of Extra-Hepatic Cholestasis Induced by Common Bile Duct Ligation.

Authors:  Pedro L R Guedes; Carolina P F Carvalho; Adriana A F Carbonel; Manuel J Simões; Marcelo Y Icimoto; Jair A K Aguiar; Maria Kouyoumdjian; Marcos L Gazarini; Marcia R Nagaoka
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

4.  Differences in metabolites of different tongue coatings in patients with chronic hepatitis B.

Authors:  Yu Zhao; Xiao-Jun Gou; Jian-Ye Dai; Jing-Hua Peng; Qin Feng; Shu-Jun Sun; Hui-Juan Cao; Ning-Ning Zheng; Jun-Wei Fang; Jian Jiang; Shi-Bing Su; Ping Liu; Yi-Yang Hu; Yong-Yu Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

5.  Urinary Metabolomic Profiling in Chronic Hepatitis B Viral Infection Using Gas Chromatography/Mass Spectrometry

Authors:  Kanthanadon Dittharot; Paisan Jittorntam; Prapin Wilairat; Abhasnee Sobhonslidsuk
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.